Almirall’s Loss of Aclidinium Could Be Glenmark’s Gain

MUMBAI - Hopes for oglemilast, Glenmark's chronic obstructive pulmonary disease candidate being developed by U.S.-based Forest Laboratories brightened after rival experimental drug aclidinium - also licensed by Forest - showed disappointing results in Phase III studies